Evolving use and clinical outcomes of coronary intravascular lithotripsy: insights from an international, multicentre registry
- PMID: 39472046
- DOI: 10.1136/heartjnl-2024-324703
Evolving use and clinical outcomes of coronary intravascular lithotripsy: insights from an international, multicentre registry
Abstract
Background: Intravascular lithotripsy (IVL) is increasingly used for treatment of coronary artery calcification. This study aimed to evaluate contemporary utilisation patterns, safety and efficacy of IVL in an unselected real-world patient cohort.
Methods: We included 454 patients undergoing IVL from May 2019 to February 2024 across seven centres in two European countries. Key endpoints included device success, technical success, procedural success, IVL-related complications and major adverse cardiovascular events (MACE) at 1-year follow-up.
Results: The cohort (mean age 73±9 years, 75% male) had a mean SYNTAX Score of 22.0±13.6. Device, technical and procedural success were achieved in 98%, 91% and 89% of patients, respectively. IVL-related complications occurred in six patients (1%). At 1-year follow-up, MACE was observed in 37 patients (13%). Over time, IVL use increased in patients with acute coronary syndrome (p=0.004) and in combination with intracoronary imaging (p=0.002), while use of other calcium modification devices decreased (p=0.034).
Conclusion: In this real-world registry, IVL demonstrated efficacy across diverse clinical and anatomical settings. High success rates, low complication rates and MACE rates were observed acutely and at 1-year follow-up. Utilisation patterns evolved over time, with increased adoption in acute scenarios and alongside intracoronary imaging.
Keywords: Coronary Artery Disease; Coronary Stenosis; Percutaneous Coronary Intervention.
© Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.
Conflict of interest statement
Competing interests: The Department of Cardiology of the Leiden University Medical Center received unrestricted research grants from Abbott Vascular, Bayer, Biotronik, Boston Scientific, Edwards Lifesciences, GE Healthcare and Medtronic. BEPMC reports relations with Sanofi, Philips, Amgen, Boston Scientific and Abiomed that include consulting or advisory. JK has served as proctor for Abbott. FvdK received consultancy fees from Edwards Lifesciences and Abbott Vascular. JMM-C received a research grant from Shockwave Medical and speaker fees from Abiomed, Boston Scientific and Penumbra.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical